This paper describes work to develop a novel human antibody nasal spray as a prophylactic treatment against SARS-CoV-2. Formulations were developed at two protein concentrations and assessed for delivery using an Aptar VP3 nasal spray pump. Both formulations were shown to be suitable for nasal delivery in terms of pH, osmolality, and delivered droplet size; no evidence of protein agglomeration was observed as a result of spraying. Further studies are planned to investigate the stability of the developed products and to establish pharmacokinetics and pharmacodynamics.
Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery
This Might Also Be of Interest
Accelerating the development of COVID vaccines and therapeutics
Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions
Aptar Pharma expert Q&A on digital health and connected drug delivery
Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Product Solutions
Aptar Pharma discusses Article 117 of the Medical Device Regulations
Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions
Drug Delivery Systems & Services for Lifecycle Management of Crisis Medications ...
Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Product Solutions
